139 related articles for article (PubMed ID: 31566408)
1. Shadows in the current management of hepatocellular carcinoma in Spain - An embarrassing truth.
Crespo J; Andrade RJ
Rev Esp Enferm Dig; 2019 Oct; 111(10):727-730. PubMed ID: 31566408
[TBL] [Abstract][Full Text] [Related]
2. The role of sorafenib in hepatocellular carcinoma.
Gholam P
Clin Adv Hematol Oncol; 2015 Apr; 13(4):232-4. PubMed ID: 26352581
[No Abstract] [Full Text] [Related]
3. Molecular targeted therapy of advanced hepatocellular carcinoma beyond sorafenib.
Yau T; Pang R; Chan P; Poon RT
Expert Opin Pharmacother; 2010 Sep; 11(13):2187-98. PubMed ID: 20707757
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular carcinoma: the role of the North American GI Steering Committee Hepatobiliary Task Force and the advent of effective drug therapy.
O'Neil BH; Venook AP
Oncologist; 2007 Dec; 12(12):1425-32. PubMed ID: 18165619
[TBL] [Abstract][Full Text] [Related]
5. The hepatocellular carcinoma market.
Dawkins J; Webster RM
Nat Rev Drug Discov; 2019 Jan; 18(1):13-14. PubMed ID: 30168534
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness analysis of antiviral therapy in patients with advanced hepatitis B virus-related hepatocellular carcinoma treated with sorafenib.
Zhang P; Yang Y; Wen F; Wheeler J; Fu P; Li Q
J Gastroenterol Hepatol; 2016 Dec; 31(12):1978-1985. PubMed ID: 27118432
[TBL] [Abstract][Full Text] [Related]
7. The evolving landscape of systemic treatment for advanced hepatocellular carcinoma and biliary tract cancer.
Rizzo A
Cancer Treat Res Commun; 2021; 27():100360. PubMed ID: 33799005
[No Abstract] [Full Text] [Related]
8. Multiple Approvals, Celestial Prices, Unimproved Outcomes: The Tale of Cost-Ineffective Drugs in Hepatocellular Carcinoma.
Gyawali B
J Natl Compr Canc Netw; 2019 Jun; 17(6):760-762. PubMed ID: 31200350
[No Abstract] [Full Text] [Related]
9. Sorafenib in advanced hepatocellular carcinoma.
Palmer DH
N Engl J Med; 2008 Dec; 359(23):2498; author reply 2498-9. PubMed ID: 19065750
[No Abstract] [Full Text] [Related]
10. Systemic therapy for hepatocellular carcinoma.
Thomas MB
Cancer J; 2008; 14(2):123-7. PubMed ID: 18391618
[TBL] [Abstract][Full Text] [Related]
11. Treatment Patterns and Economic Burden by Lines of Therapy Among Patients with Advanced Hepatocellular Carcinoma Treated with Systemic Cancer Therapy.
Bonafede MM; Korytowsky B; Singh P; Cai Q; Cappell K; Jariwala-Parikh K; Sill B; Parikh ND
J Gastrointest Cancer; 2020 Mar; 51(1):217-226. PubMed ID: 31011982
[TBL] [Abstract][Full Text] [Related]
12. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
13. Impact of restricting access to high-cost medications for hepatocellular carcinoma.
Ma YT; Palmer DH
Expert Rev Pharmacoecon Outcomes Res; 2012 Aug; 12(4):465-73. PubMed ID: 22971033
[TBL] [Abstract][Full Text] [Related]
14. From a cancer drug fund to value based pricing of drugs.
Duerden M
BMJ; 2010 Aug; 341():c4388. PubMed ID: 20705656
[No Abstract] [Full Text] [Related]
15. Trends in the development of MET inhibitors for hepatocellular carcinoma.
Okuma HS; Kondo S
Future Oncol; 2016 May; 12(10):1275-86. PubMed ID: 26984595
[TBL] [Abstract][Full Text] [Related]
16. [Therapeutic decisions in the treatment of hepatocellular carcinoma and patterns of sorafenib use. Results of the international observational GIDEON trial in Spain].
Turnes J; Díaz R; Hernandez-Guerra M; Gómez M; Castells L; Bustamante J; Espinosa MD; Fernández-Castroagudín J; Serrano T; Rendón P; Andrade R; Salgado M; Arenas J; Vergara M; Sala M; Polo BA; Granizo IM; Gonzálvez ML; Viudez A
Gastroenterol Hepatol; 2015 Apr; 38(4):263-73. PubMed ID: 25583146
[TBL] [Abstract][Full Text] [Related]
17. [Recommendations for the management of Sorafenib in patients with hepatocellular carcinoma].
Reig M; Matilla A; Bustamante J; Castells L; de La Mata M; Delgado M; Moreno JM; Forner A; Varela M
Gastroenterol Hepatol; 2010 Dec; 33(10):741-52. PubMed ID: 20851505
[No Abstract] [Full Text] [Related]
18. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
Chen J; Jin R; Zhao J; Liu J; Ying H; Yan H; Zhou S; Liang Y; Huang D; Liang X; Yu H; Lin H; Cai X
Cancer Lett; 2015 Oct; 367(1):1-11. PubMed ID: 26170167
[TBL] [Abstract][Full Text] [Related]
19. Novel treatments for hepatocellular cancer.
Kerr SH; Kerr DJ
Cancer Lett; 2009 Dec; 286(1):114-20. PubMed ID: 19664880
[TBL] [Abstract][Full Text] [Related]
20. Extending survival with the use of targeted therapy in the treatment of hepatocellular carcinoma.
Gish RG; Finn RS; Marrero JA
Clin Adv Hematol Oncol; 2013 Apr; 11 Suppl 5():1-22; quiz 2 p following p22. PubMed ID: 23881427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
